Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Serious adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Serious adverse events · people with active UC
Antibiotics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
Serious adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review